[Inhibition of growth and dissolution of crystalline drugs].
作者信息
Tawashi R, Piccolo J
出版信息
Pharm Acta Helv. 1970 Nov;45(11):653-77.
PMID:4924221
Abstract
摘要
相似文献
1
[Inhibition of growth and dissolution of crystalline drugs].
Pharm Acta Helv. 1970 Nov;45(11):653-77.
2
3
Inhibited dissolution of drug crystals by certified water soluble dyes in micellar bile acid solutions.
Pharm Acta Helv. 1975;50(6):184-7.
4
[Significance of the pertinent crystalline condition for the sorptive inhibition of the solution process].
Pharmazie. 1977 Jun 6;32(6):354-5.
5
6
A model of dissolution-controlled solute release from porous drug delivery polymeric systems.
J Biomed Mater Res. 1983 Nov;17(6):1079-87. doi: 10.1002/jbm.820170615.
7
[Amelioration and normalization of the rapidity of dissolution by microcrystallization: application to methylprednisolone].
J Pharm Belg. 1971 Mar-Apr;26(2):115-34.
8
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
Adv Drug Deliv Rev. 2007 Jul 30;59(7):617-30. doi: 10.1016/j.addr.2007.05.011. Epub 2007 May 29.
9
Particle design of poorly water-soluble drug substances using supercritical fluid technologies.
Adv Drug Deliv Rev. 2008 Feb 14;60(3):388-98. doi: 10.1016/j.addr.2007.03.025. Epub 2007 Oct 11.
10
Amorphous drug nanosuspensions. 3. Particle dissolution and crystal growth.
Langmuir. 2007 Sep 11;23(19):9866-74. doi: 10.1021/la700811b. Epub 2007 Aug 15.
Zotero 插件